Some states now allow dispensing of oral anticancer medications via practice-based pharmacies. In this segment, Michael Kolodziej, MD, and Ted Okon, MBA, consider the impact of establishing a dispensing pharmacy within a practice.
Dr Kolodziej remarks that although these pharmacies permit patients to receive their medications at their doctor’s office, barriers and concerns including prior authorizations, co-payment costs, and patient adherence remain. Additionally, small practices are not able to negotiate with payers for volume discounts. Comparative effectiveness research could play an important role in addressing some of these issues, suggests Dr Kolodziej.
Many practices have reached out to the Community Oncology Alliance (COA) looking for support and information about operating pharmacies within their practices, notes Mr Okon. To assist practices, the COA recently established the Community Oncology Pharmacy Association to help establish quality standards, among other goals.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More